BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21504712)

  • 1. High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy.
    Kreisel F; Kulkarni S; Kerns RT; Hassan A; Deshmukh H; Nagarajan R; Frater JL; Cashen A
    Cancer Genet; 2011 Mar; 204(3):129-37. PubMed ID: 21504712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma.
    Sebastián E; Alcoceba M; Martín-García D; Blanco Ó; Sanchez-Barba M; Balanzategui A; Marín L; Montes-Moreno S; González-Barca E; Pardal E; Jiménez C; García-Álvarez M; Clot G; Carracedo Á; Gutiérrez NC; Sarasquete ME; Chillón C; Corral R; Prieto-Conde MI; Caballero MD; Salaverria I; García-Sanz R; González M
    Ann Hematol; 2016 Jan; 95(2):253-62. PubMed ID: 26573278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas.
    Robledo C; García JL; Caballero D; Conde E; Arranz R; Flores T; Grande C; Rodríguez J; García E; Sáez AI; González M; Gutiérrez NC; Piris MA; Hernández JM;
    Cancer; 2009 Aug; 115(16):3728-37. PubMed ID: 19517471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
    Tagawa H
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases.
    Tagawa H; Tsuzuki S; Suzuki R; Karnan S; Ota A; Kameoka Y; Suguro M; Matsuo K; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
    Cancer Res; 2004 Sep; 64(17):5948-55. PubMed ID: 15342373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Array-based comparative genomic hybridization analysis reveals chromosomal copy number aberrations associated with clinical outcome in canine diffuse large B-cell lymphoma.
    Aricò A; Ferraresso S; Bresolin S; Marconato L; Comazzi S; Te Kronnie G; Aresu L
    PLoS One; 2014; 9(11):e111817. PubMed ID: 25372838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma.
    Chang CC; Zhou X; Taylor JJ; Huang WT; Ren X; Monzon F; Feng Y; Rao PH; Lu XY; Fabio F; Hilsenbeck S; Creighton CJ; Jaffe ES; Lau CC
    J Hematol Oncol; 2009 Nov; 2():47. PubMed ID: 19909553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 12. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.
    Jardin F; Jais JP; Molina TJ; Parmentier F; Picquenot JM; Ruminy P; Tilly H; Bastard C; Salles GA; Feugier P; Thieblemont C; Gisselbrecht C; de Reynies A; Coiffier B; Haioun C; Leroy K
    Blood; 2010 Aug; 116(7):1092-104. PubMed ID: 20435884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
    Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
    Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
    Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
    Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.
    Jardin F; Ruminy P; Kerckaert JP; Parmentier F; Picquenot JM; Quief S; Villenet C; Buchonnet G; Tosi M; Frebourg T; Bastard C; Tilly H
    Haematologica; 2008 Apr; 93(4):543-50. PubMed ID: 18287131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma.
    Dias LM; Thodima V; Friedman J; Ma C; Guttapalli A; Mendiratta G; Siddiqi IN; Syrbu S; Chaganti RS; Houldsworth J
    Leuk Lymphoma; 2016; 57(4):899-908. PubMed ID: 26294112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of copy number gains and losses, detected by array-based comparative genomic hybridization, for computational differential diagnosis of B-cell lymphomas and genetic regions involved in lymphomagenesis.
    Takeuchi I; Tagawa H; Tsujikawa A; Nakagawa M; Katayama-Suguro M; Guo Y; Seto M
    Haematologica; 2009 Jan; 94(1):61-9. PubMed ID: 19029149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas.
    Belaud-Rotureau MA; Marietta V; Vergier B; Mainhaguiet G; Turmo M; Idrissi Y; Ferrer J; Beylot-Barry M; Dubus P; Merlio JP
    Virchows Arch; 2008 Jun; 452(6):607-20. PubMed ID: 18311490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.